- Home
- CPRI vs CGON Comparison
CPRI vs CGON Comparison
Compare CPRI & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPRI
- CGON
- Stock Information
- Founded
- CPRI 1981
- CGON 2010
- Country
- CPRI United Kingdom
- CGON United States
- Employees
- CPRI N/A
- CGON N/A
- Industry
- CPRI Apparel
- CGON
- Sector
- CPRI Consumer Discretionary
- CGON
- Exchange
- CPRI Nasdaq
- CGON NYSE
- Market Cap
- CPRI 1.6B
- CGON 1.3B
- IPO Year
- CPRI 2011
- CGON 2024
- Fundamental
- Price
- CPRI $16.89
- CGON $23.74
- Analyst Decision
- CPRI Buy
- CGON Strong Buy
- Analyst Count
- CPRI 11
- CGON 11
- Target Price
- CPRI $24.18
- CGON $62.90
- AVG Volume (30 Days)
- CPRI 3.1M
- CGON 2.0M
- Earning Date
- CPRI 05-28-2025
- CGON 05-20-2025
- Dividend Yield
- CPRI N/A
- CGON N/A
- EPS Growth
- CPRI N/A
- CGON N/A
- EPS
- CPRI N/A
- CGON N/A
- Revenue
- CPRI $4,630,000,000.00
- CGON $1,139,000.00
- Revenue This Year
- CPRI N/A
- CGON N/A
- Revenue Next Year
- CPRI N/A
- CGON $16,237.24
- P/E Ratio
- CPRI N/A
- CGON N/A
- Revenue Growth
- CPRI N/A
- CGON 461.08
- 52 Week Low
- CPRI $11.86
- CGON $14.80
- 52 Week High
- CPRI $43.34
- CGON $40.47
- Technical
- Relative Strength Index (RSI)
- CPRI 57.45
- CGON 49.91
- Support Level
- CPRI $15.05
- CGON $21.00
- Resistance Level
- CPRI $15.86
- CGON $30.23
- Average True Range (ATR)
- CPRI 0.62
- CGON 2.33
- MACD
- CPRI 0.47
- CGON 0.06
- Stochastic Oscillator
- CPRI 93.32
- CGON 30.94
About CPRI Capri Holdings Limited
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Michael Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 700 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.